The ACROSS-China trial
| ISRCTN | ISRCTN69559777 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN69559777 |
| Protocol serial number | ACROSS-protocol 5 |
| Sponsor | Bayer (China) Limited |
| Funders | Bayer (China) Limited, 11th Five-year National Supporting Schedule of Science and Technology (China) |
- Submission date
- 05/01/2008
- Registration date
- 29/05/2008
- Last edited
- 29/05/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Yongjun Wang
Scientific
Scientific
Beijing Tiantan Hospital
Tiantan Xili 6
Chongwen District
Beijing
100050
China
Study information
| Primary study design | Observational |
|---|---|
| Study design | Multicentre observational, prospective, cohort study |
| Secondary study design | Cohort study |
| Study type | Participant information sheet |
| Scientific title | Abnormal gluCose Regulation in patients with acute strOke acroSS China: a national multicentre prospective study |
| Study acronym | ACROSS-China |
| Study objectives | 1. The prevalence of abnormal glucose regulation in patients with acute stroke is high 2. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation 3. Patients with or without abnormal glucose regulation will have different outcomes and recurrent risk of stroke 4. Different subtypes of abnormal glucose regulation have different effects on the outcomes and recurrence of stroke |
| Ethics approval(s) | Ethics approval received from the Tiantan Hospital Ethics Committee on the 28th August 2007 |
| Health condition(s) or problem(s) studied | Abnormal glucose regulation, acute stroke |
| Intervention | All participants without a history of diabetes mellitus will be identified as having abnormal glucose regulation or not by using the oral glucose tolerance test (OGTT) three days before discharge. The outcome and recurrence of stroke will be compared between the patients with and without abnormal glucose regulation respectively at three months and one year after the onset of stroke as below: 1. Modified Rankin Scale (mRS) 2. The times of stroke recurrence The current therapy measures of abnormal glucose regulation in patients with acute stroke will be observed during in-hospital and follow-up. |
| Intervention type | Other |
| Primary outcome measure(s) |
The prevalence of abnormal glucose regulation after acute stroke in China, measured by OGTT before discharge. |
| Key secondary outcome measure(s) |
1. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation |
| Completion date | 01/09/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 4000 |
| Key inclusion criteria | 1. Older than 18, either sex 2. Acute stroke: diagnosed on World Health Organization (WHO) criteria 3. Acute primary stroke patients within 14 days |
| Key exclusion criteria | 1. Cerebral infarction without symptoms and signs 2. Non-cerebrovascular events 3. Stroke patients out of 14 days 4. Without the content of patients or their legal agents |
| Date of first enrolment | 01/01/2008 |
| Date of final enrolment | 01/09/2008 |
Locations
Countries of recruitment
- China
Study participating centre
Beijing Tiantan Hospital
Beijing
100050
China
100050
China
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
